BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Thyroid cancer AND AXIN1, LA16c-314G4_3, 8312, ENSG00000103126, O15169, AXIN, MGC52315 AND Clinical Outcome
199 results:

  • 1. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
    Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
    Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Impact of a mobile health intervention based on multi-theory model of health behavior change on self-management in patients with differentiated thyroid cancer: protocol for a randomized controlled trial.
    Jiang Y; Sun X; Jiang M; Min H; Wang J; Fu X; Qi J; Yu Z; Zhu X; Wu Y
    Front Public Health; 2024; 12():1327442. PubMed ID: 38282759
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
    Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
    Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
    La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
    Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
    Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
    Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.
    Bandoh N; Goto T; Kato Y; Kubota A; Sakaue S; Takeda R; Hayashi S; Hayashi M; Baba S; Yamaguchi-Isochi T; Nishihara H; Kamada H
    Asian J Surg; 2024 Jan; 47(1):413-419. PubMed ID: 37752023
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The impact of microscopic extrathyroidal extension on the clinical outcome of classic subtype papillary thyroid microcarcinoma: a multicenter study.
    Zuhur SS; Aggul H; Avci U; Erol S; Tuna MM; Uysal S; Akbaba G; Kilinc F; Catak M; Tekin S; Ozturk BO; Yavuz HC; Kadioglu P; Cinar N; Bayraktaroglu T; Topcu B; Altuntas Y; Elbuken G
    Endocrine; 2024 Mar; 83(3):700-707. PubMed ID: 37736822
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Efficacy and safety of microwave ablation for the treatment of multifocal versus unifocal T1N0M0 papillary thyroid carcinoma: a propensity-matched multicentre retrospective study.
    Zhao ZL; Dong G; Wang SR; Liu Y; He JF; Shi LL; Guo JQ; Wang ZH; Cong ZB; Liu LH; Yang BB; Qu CP; Wei Y; Peng LL; Li Y; Lu NC; Wu J; Yu MA
    Eur Radiol; 2023 Dec; 33(12):8727-8735. PubMed ID: 37466709
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. No Association of Preablation Thyroglobulin Antibody Positivity and outcome in Pediatric Patients With Papillary thyroid Carcinoma.
    Xu Y; Shi L; Wu J; Li H; Wang Y; Liu B
    Clin Nucl Med; 2023 Sep; 48(9):763-767. PubMed ID: 37385237
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Incidentally detected 18 F-FDG PET-CT-avid thyroid nodules in patients with advanced malignancy: long-term oncological outcomes from a single-centre retrospective cohort.
    Owens C; Fitzhugh A; Harrington K; Paleri V; Sharma B; Shur J; Ap Dafydd D
    Nucl Med Commun; 2023 Sep; 44(9):810-815. PubMed ID: 37272278
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
    Staubitz JI; Müller C; Heymans A; Merten C; Roos B; Poplawski A; Ludt A; Strobl S; Springer E; Schad A; Roth W; Musholt TJ; Hartmann N
    BJS Open; 2023 May; 7(3):. PubMed ID: 37146205
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Magnetic resonance diagnosis of laryngeal chondritis after transoral laser microsurgery for laryngeal cancer.
    Cunha B; Lancini D; Rondi P; Ravanelli M; Maroldi R; Paderno A; Zigliani G; Bertotto I; Piazza C; Farina D
    Acta Otorhinolaryngol Ital; 2023 Feb; 43(1):32-41. PubMed ID: 36860148
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression.
    Shi Q; Yu J; Liu D; Ren F; Wu J; Shen K
    BMC Cancer; 2023 Feb; 23(1):173. PubMed ID: 36810001
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Do Histologically Aggressive Subtypes of Papillary thyroid Microcarcinoma have Worse clinical outcome than Non-Aggressive Papillary thyroid Microcarcinoma Subtypes? A Multicenter Cohort Study.
    Zuhur SS; Aggul H; Avci U; Erol S; Tuna MM; Uysal S; Akbaba G; Kilinç F; Catak M; Tekin S; Bilen OI; Öztürk BO; Erden EB; Elbuken G; Yavuz HC; Kadioglu P; Cinar N; Kutluturk F; Bayraktaroglu T; Topçu B; Arslan AI; Gucer H; Cihangiroglu G; Topal CS; Ozturk T; Tekin L; Artas G; Akcay E; Gun BD; Altuntas Y
    Horm Metab Res; 2023 May; 55(5):323-332. PubMed ID: 36764327
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Positive
    Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
    Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.
    Kafka M; Burtscher T; Fritz J; Schmitz M; Bektic J; Ladurner M; Horninger W; Heidegger I
    World J Urol; 2023 Aug; 41(8):2043-2050. PubMed ID: 36287244
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Dacryoendoscopic Findings of Patients with Lacrimal Drainage Obstruction Associated with cancer Treatment.
    Kim Y; Lew H
    Korean J Ophthalmol; 2022 Dec; 36(6):509-517. PubMed ID: 36220641
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. clinical characteristics and prognostic nomogram for patients with insular thyroid carcinoma: a population-based analysis.
    Yin L; Hou S; Hou LL; Pu CC
    Endocrine; 2023 Feb; 79(2):331-341. PubMed ID: 36207552
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Is multifocality a risk factor in low-risk papillary thyroid cancer?
    Sapuppo G; Grasso S; Di Benedetto G; Marturano I; Costanzo G; Belfiore A; Pellegriti G
    Endokrynol Pol; 2022; 73(6):928-934. PubMed ID: 36094871
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Analysis of Delayed Surgery and clinical outcomes in Intermediate- and High-risk Papillary thyroid cancer.
    Zhou H; Wu J; Shi L; Wang Y; Liu B
    J Clin Endocrinol Metab; 2022 Nov; 107(12):3389-3397. PubMed ID: 36056633
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 10.